Efficacy and Safety of PD-1 Inhibitor Plus Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

被引：0
|
作者：
Qin, Yan [1 ]
He, Xiaohui [1 ]
Yang, Sheng [1 ]
Liu, Peng [1 ]
Zhou, Shengyu [1 ]
Yang, Jianliang [1 ]
Gui, Lin [1 ]
Zhong, Qiaofeng [1 ]
Zhao, Fengyi [1 ]
Shi, Yuankai [1 ]
Jing, Hongmei [2 ]
Zhang, Shiyue [3 ]
Guo, Ruihan [3 ]
Shi, Yuankai [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Beijing Key Lab Clin Study Anticanc Mol Targete, Dept Med Oncol, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[2] Peking Univ Third Hosp, Dept Hematol, Beijing, Peoples R China
[3] Shanghai Junshi Biosci, Shanghai, Peoples R China
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-152094
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2485
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis
    Merchionne, Francesca
    Quintana, Giovanni
    Gaudio, Francesco
    Minoia, Carla
    Specchia, Giorgina
    Guarini, Attilio
    Quarta, Giovanni
    Pavone, Vincenzo
    Melpignano, Angela
    LEUKEMIA RESEARCH, 2014, 38 (12) : 1446 - 1450
  • [32] BENDAMUSTINE PLUS RITUXIMAB FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: A RETROSPECTIVE STUDY
    Merchionne, F.
    Quintana, G.
    Minoia, C.
    Guarini, A.
    Galise, I.
    Quarta, G.
    Loseto, G.
    Melpignano, A.
    HAEMATOLOGICA, 2014, 99 : 696 - 697
  • [33] Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients
    Zinzani, Pier Luigi
    Pellegrini, Cinzia
    Derenzini, Enrico
    Argnani, Lisa
    Pileri, Stefano
    HEMATOLOGICAL ONCOLOGY, 2013, 31 (04) : 223 - 224
  • [34] Clinical Efficacy and Safety in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Systematic Literature Review
    Colosia, Ann
    Njue, Annete
    Trask, Peter C.
    Olivares, Robert
    Khan, Shahnaz
    Abbe, Adeline
    Police, Rachel
    Wang, Jianmin
    Ruiz-Soto, Rodrigo
    Kaye, James A.
    Awan, Farrukh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05): : 343 - 355
  • [35] Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma
    Jeffrey L. Vacirca
    Peter. I. Acs
    Imad A. Tabbara
    Peter. J. Rosen
    Peter Lee
    Eric Lynam
    Annals of Hematology, 2014, 93 : 403 - 409
  • [36] PD-1 expression on tumour-infiltrating cells is a prognostic factor for relapsed or refractory diffuse large B-cell lymphoma
    Wada, Fumiya
    Kamijo, Kimimori
    Shimomura, Yoshimitsu
    Yamashita, Daisuke
    Hara, Shigeo
    Ishikawa, Takayuki
    IMMUNOLOGY, 2024, 171 (02) : 224 - 234
  • [37] Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma
    Vacirca, Jeffrey L.
    Acs, Peter I.
    Tabbara, Imad A.
    Rosen, Peter J.
    Lee, Peter
    Lynam, Eric
    ANNALS OF HEMATOLOGY, 2014, 93 (03) : 403 - 409
  • [38] Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
    Yuan, Xianggui
    Li, Xian
    Huang, Yurong
    Jin, Xueli
    Liu, Hui
    Zhao, Aiqi
    Zhang, Weiping
    Qian, Wenbin
    Liang, Yun
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [39] Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab
    Sud, Rohit
    Friedberg, Jonathan W.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 (12): : 1776 - 1780
  • [40] Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma
    Lu, Q.
    Huang, H.
    Tang, S.
    Wang, Y.
    Yang, D-H
    DRUGS OF TODAY, 2021, 57 (09) : 571 - 580
12345